{
    "id": "61541034",
    "text": "Adavosertib (development codes AZD1775, MK-1775) is an experimental anti- cancer drug candidate. It is a small molecule inhibitor of the tyrosine kinase WEE1 with potential antineoplastic sensitizing activity. It is being developed by AstraZeneca.It is being investigated as a treatment for pancreatic cancer with phase 1 trial. University of Michigan researchers are as of 2019 planning a phase 2 study. ==References== Category:Experimental cancer drugs Category:Piperazines Category:Pyridines Category:AstraZeneca brands Category:Tertiary alcohols Category:Tyrosine kinase inhibitors ",
    "title": "Adavosertib"
}